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BACKGROUND: To date individual markers have failed to correctly predict resistance against anticancer agents in breast cancer. We
used gene expression patterns attributable to chemotherapy-resistant cells to detect potential new biomarkers related to
anthracycline resistance. One of the genes, PSMB7, was selected for further functional studies and clinical validation.
METHODS: We contrasted the expression profiles of four pairs of different human tumour cell lines and of their counterparts resistant
to doxorubicin. Observed overexpression of PSMB7 in resistant cell lines was validated by immunohistochemistry. To examine its
function in chemoresistance, we silenced the gene by RNA interference (RNAi) in doxorubicin-resistant MCF-7 breast cancer cells,
then cell vitality was measured after doxorubicin treatment. Microarray gene expression from GEO raw microarray samples with
available progression-free survival data was downloaded, and expression of PSMB7 was used for grouping samples.
RESULTS: After doxorubicin treatment, 79.8±13.3% of resistant cells survived. Silencing of PSMB7 in resistant cells decreased survival
to 31.8±6.4% (P40.001). A similar effect was observed after paclitaxel treatment. In 1592 microarray samples, the patients with high
PSMB7 expression had a significantly shorter survival than the patients with low expression (Po0.001).
CONCLUSION: Our findings suggest that high PSMB7 expression is an unfavourable prognostic marker in breast cancer.
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The major cause of cancer therapy failure is either primary drug
resistance or the development of secondary resistance against
currently available antineoplastic agents. Many different mechan-
isms of drug resistance have been identified, including the
overexpression of members of the family of adenosine tripho-
sphate-binding cassette (ABC)-transporters such as P-glycoprotein
(ABCB1), the multidrug resistance-associated proteins MRP1 and
MRP2 and the mitoxantrone resistance protein/breast cancer
resistance protein (Gottesman et al, 2002). Drug resistance is also
mediated by defects in intrinsic cellular safeguard mechanisms
capable of activating apoptosis. The loss of programmed cell death
induced by antitumour drugs can be achieved through disruption
of regulators of DNA damage signalling, such as p53 and bcl-2.
Moreover, alterations in cell cycle checkpoints, repair of damaged
cellular targets and various additional more or less well-
characterised mechanisms can contribute to the resistance.
The anthracycline antibiotic doxorubicin (adriamycin) is widely
used for treatment of breast, ovarian, bronchogenic and gastric
solid tumours, lymphomas and leukaemias (Martin et al, 2003).
Triple negative (ER-, PR-, HER2-) breast patients receive
anthracycline-based chemotherapeutic agents in monotherapy or
in combination protocols. Although a number of different
mechanisms have been proposed for the cytotoxic effect of
anthracyclines, the primary mechanism of drug action is likely
to be the inhibition of DNA biosynthesis through topoisomerase II
binding and consequently conferring an S/G2 cell cycle arrest
(Gewirtz, 1999). As a topoisomerase inhibitor, it potentially
induces apoptosis in normal cells as well (Sabourin and Osheroff,
2000).
In several reports, authors applied DNA array technologies to
find genes correlated with doxorubicin resistance (Ayers et al,
2004; Kang et al, 2004; Folgueira et al, 2005; Gianni et al, 2005;
Cleator et al, 2006; Gyorffy et al, 2006; Hess et al, 2006). In our
earlier study, we used gene expression patterns of closely related
chemotherapy-resistant and -sensitive parental cancer cell lines to
identify discriminatory genes associated with drug resistance. The
use of a set of different cell lines for the identification of
discriminating genes allows a tissue-independent application for
predicting therapy response. We applied our model to predict
sensitivity in a set of 44 breast cancer samples. The patient group
characterised by the gene expression profile similar to that of
drug-sensitive cell lines exhibited over 50% longer survival than
the group exhibiting the profile characteristic of resistant cells
(Gyorffy et al, 2005). Overall, in these gene expression signatures, a
considerable number of genes were associated with doxorubicin
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sresistance. However, it is desirable to discriminate markers
associated with treatment response and markers responsible for
resistance.
The proteasome is a multicatalytic proteinase complex with a
highly ordered ring-shaped 20S core structure. The core structure
is composed of 4 rings of 28 non-identical subunits; 2 rings are
composed of 7 a subunits and 2 rings are composed of 7 b
subunits. Proteasomes are distributed throughout eukaryotic cells
at a high concentration and cleave damaged and needless peptides
in an ATP/ubiquitin-dependent process in a non-lysosomal
pathway. Proteasome inhibitors are drugs blocking the action of
cellular complexes that break down proteins. They have an
antitumour activity in cell culture, and induce apoptosis by
disturbing regulation of cell cycle proteins (Adams et al, 1999).
Bortezomib was the first proteasome inhibitor, which is already
used in clinics as a chemotherapy agent (Kane et al, 2006).
Bortezomib effectively eradicates myelome multiplex by activating
the stress apoptosis signal of endoplasmic reticulum (Schewe and
guirre-Ghiso, 2009). So far, several studies examined its effect on
proteasomes in different circumstances (Ludwig et al, 2005;
Montagut et al, 2005; Montagut et al, 2006; Sterz et al, 2008).
Proteasome inhibitors might also increase chemosensitivity.
Cotreatment of doxorubicin and bortezomib can conversely
increase the efficiency of each other (Ciolli et al, 2008). However,
to date the direct association with doxorubicin resistance as well as
the potential prognostic or predictive value of selected proteasome
subunits has not been investigated.
In this study, our intention was to identify gene expression
signatures obtained from resistant cells in long-term
culture, untreated sensitive parental cells and parental cells after
short-term drug administration. On the basis of relevance in
clinical samples, we selected one proteasome subunit, the
proteasome unit b-type 7 (PSMB7) for further examination using
RNA interference (RNAi) to validate its function in doxorubicin
resistance. Our aim was also to identify effects of paclitaxel cross-
resistance on the resistant cell line. Finally, microarray data from
1592 patients were used to examine the clinical relevance of
PSMB7.
MATERIALS AND METHODS
Cell lines
The doxorubicin/daunorubicin-resistant derivatives of human
gastric carcinoma cell line EPG85-257P, pancreatic carcinoma cell
line EPP85-181P, colon carcinoma cell line HT-29 and breast
cancer cell line MCF-7 were established in our laboratory as
described earlier (Lage and Dietel, 2002). Cells were cultured in
Leibovitz L-15 medium (Sigma-Aldrich, Budapest, Hungary)
supplemented with 10% foetal calf serum (Life Sciences, Grand
Island, NY, USA), 1mML -glutamine, 80 IE/l insulin, 2.5mgl
–1
transferrin, 1gl
–1glucose, 1.1gl
–1NaHCO3, 1% minimal essential
vitamins and 20000kIEl
–1 trasylol in a humified atmosphere
containing 5% CO2 at 371C. Culture media of resistant cell lines
were supplemented with daunorubicin for HT-29 (0.125mgml
–1),
EPP85-181 (2.5mgml
–1) and EPG-257 (2.5mgml
–1) and doxor-
ubicin (0.05mgml
–1) for MCF-7 cells (Farmitalia Carlo Erba,
Freiburg, Germany). The 24h treatment of drug-sensitive cells was
performed at the identical drug concentrations.
Sensitivity of cells to doxorubicin and paclitaxel
Cell proliferation assay (Cell Proliferation Kit I (MTT) Roche, IN,
USA,) was used to monitor sensitivity of doxorubicin-resistant cell
lines. Protocol was carried out as directed by the manufacturer.
Briefly, 5000 cells per well in a microplate were plated, and drug
was added after an overnight incubation in increasing grade of
0.0001x–100x of the clinically administered dose (doxorubicin:
0.02mgml
–1, paclitaxel: 0.025mgml
–1) in triplicates. Six days later,
MTT (3-[4, 5-dimethylthiazolyl-2]-2, 5-diphenyltetrazolium bro-
mide) was added to each well for 4h. After this incubation period,
the formed purple formazan salt crystals were solubilised and
quantified 1 day later with the use a BioTek PowerWave XS
Microplate Spectrophotometer.
Autofluorescence of doxorubicin
A total of 50000 sensitive MCF-7 cells per well were plated in
triplicate in a 96-well plate for four different conditions: (1) cells
treated by doxorubicin, (2) untreated cells, (3) doxorubicin in L15
medium without cells and (4) L15 medium alone. Doxorubicin
treatment (0.2mgml
–1) was carried out on the second day for 1.5h.
MTT staining and reading the results were performed as described
above. Differences were assessed by using a t-test.
RNA isolation and cDNA synthesis
RNA was isolated from 1 10
7 cells in logarithmic growth phase
using the Qiagen RNeasy Mini Kit following the manufacturer’s
protocol (Qiagen GmbH, Hilden, Germany). Isolated total RNA
was quantified by UV-spectroscopy and quality checked by
analysis on a LabChip (BioAnalyzer, Agilent Technologies, Santa
Clara, CA, USA). RNA samples were stored at  801C. cDNA was
synthesised from 5mg total RNA by firstly annealing to 5pmolml
–1
HPLC purified T7- (dT)24 primer (MWG-Biotech, Ebersberg,
Germany) at 701C for 10min. Second, reverse transcription,
second-strand synthesis and cleanup of double-stranded cDNA
was performed according to the protocols provided by Affymetrix
(http://www.affymetrix.com/index.affx). Synthesis of biotin-la-
belled cRNA was performed using the BioArray High Yield RNA
Transcription kit (Enzo Diagnostics, Farmingdale, NY, USA).
cRNA concentration was determined by UV-spectroscopy and the
distribution of cRNA fragment size was checked on a LabChip
(BioAnalyzer, Agilent Technologies).
Hybridization protocol
The fragmented cRNA was hybridised to the HG-U133A arrays
(Affymetrix, Santa Clara, CA, USA) in a hybridization oven at 451C
for 16h. Subsequent washing and staining of arrays was performed
using the GeneChip fluidics station protocol EukGE-WS2. Finally,
probe arrays were scanned using the GeneChip System confocal
scanner (Hewlett-Packard, Santa Clara, CA, USA). For each cell
line triplicates (sensitive, resistance and treated), hybridization
was made once, so altogether 12 hybridizations were made. The
microarray data can be downloaded from GEO (accession no.
GSE3926).
Pre-processing of microarray data
Quality control analysis was performed according to the sugges-
tions of The Tumor Analysis Best Practices Working Group
(Hoffman et al, 2004). Scanned images were inspected for artefacts.
All RNA targets included in the analysis exhibited present calls of
425% and were not degraded. We have applied RMA (Irizarry
et al, 2003) for the normalization of hybridization intensities. The
pre-processing was performed using Bioconductor packages in the
R statistical environment. RMA is one of the most common array
normalization methods supplying cross-project normalization
with good specificity and excellent sensitivity.
Feature selection
We arranged the complete data set into three classes according to
the resistance and treatment properties of the cell lines. We
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treated parental and resistant cell lines. For identifying discrimi-
nating genes, the Prediction Analysis for Mircorarrays (PAM
v.1.23) package was used as described earlier (Tibshirani et al,
2002). PAM uses soft thresholding for producing a shrunken
centroid, which allows the selection of genes with high discrimi-
native potential. An overview of the applied statistical approach is
presented in Figure 1. We decided to pick the top 100 genes from
each comparison for the selection of the best discriminatory group
of genes. Then genes were identified, which discriminate between
parental and treated parental cell lines (reflecting effect of the drug
treatment) and resistant and parental cell lines (reflecting genes of
resistance).
Additional analyses
Hierarchical clustering was performed using the Genesis software
(Sturn et al, 2002). Before clustering, we performed a second
normalization at the gene level to set the average expression of
each transcript to 0 to present gene inductions or repressions of
identical magnitude as numerically equal. Gene annotations were
performed using the Netaffx Analysis Centre (http://www.affymetrix.
com/analysis/index.affx).
Immunohistochemistry
Cells were grown on microscopic slides and fixed in ice-cold
methanol–acetone mixture (1:1). Activity of endogenous perox-
idase was blocked by incubation in 1% H2O2. Immunohistochem-
ical stainings were carried out in triplicate with primary antibody
polyclonal antiserum against PSMB7 (dilution 1:200; GenWay
Biotech, Inc., CA, USA). Subsequently, slides were incubated with
secondary biotinylated antibodies anti-mouse, rabbit and goat;
optimally prediluted from LSABþ, HRP Kit (DakoCytomation,
Glostrup, Denmark); followed by optimally prediluted streptavidin–
biotinylated peroxidase complex (LSABþ,H R P ,D a k o C y t o m a t i o n )
and the chromogen NovaRed (Vector Laboratories, Peterborough,
UK) at room temperature. The intensity of antigen expression was
measured using the digital imaging system Lucia-G/F (Nikon,
Tokyo, Japan). Mean saturation feature was determined in four
microscopic fields at 200-fold magnification. Nucleus staining was
performed by DAPI (40,6-diamidino-2-phenylindole).
Oligos for RNAi
Target of siRNA oligos for PSMB7 were designed using siRNA
Target Finder (http://www.ambion.com) and siDESIGN Center
(http://www.dharmacon.com) softwares. DNA oligonucleotide
templates for three target mRNAs were ordered (Csertex Kft,
Budapest, Hungary), then were synthesised by Silencer siRNA
Construction Kit (Applied Biosystems, Darmstadt, Germany) using
the manufacturer’s instruction. Synthesised siRNA duplex con-
centrations were measured by NanoDrop ND-1000 spectrophot-
ometer (BCM, Houston, TX, USA) then diluted as needed. PCR
primers were designed by Primer3 software (http://frodo.wi.mit.
edu/) and their binding site was verified by NCBI BLAST (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). Out of three synthesised siRNA
oligos, one silenced effectively PSMB7 better than 80%. Figure 3
shows binding location of every synthesised oligos and PCR
primers (effective siRNA is framed by continuous line). Effective-
ness of siRNA oligos was validated by RT–PCR (Figure 3B).
SiRNA transfection of MCF-7 cell lines
Transfection was carried out with 5ml SiPORT NeoFX Transfection
Reagent (Applied Biosystems, Budapest, Hungary) in six-well
plates. A total of 230000 cells were plated into each well. The final
concentration of siRNA was 10nM in 2.5ml serum and antibiotic-
free medium. After 24h of incubation, medium was washed twice
with sterile PBS, then normal growth medium was added. Total
RNA was extracted in the 48thh after transfection with Qiagen
RNeasy Mini Kit as described earlier, cDNA synthesis and DNA
amplification were carried out by OneStep RT–PCR Kit (Qiagen
GmbH) with gene-specific PCR primers. GAPDH was used as
internal control. We used 24 amplification cycles for amplification.
Amplification products were separated on 2% agarose gel stained
with ethidium-bromide. The effect of silencing was calculated by
Adobe Photoshop CS2 software.
Combination of RNAi and chemotherapy treatment
To investigate the function of selected gene in chemoresistance, we
combined RNAi and drug treatment. PSMB7 overexpressed in
resistant cells was silenced in doxorubicin-resistant MCF-7 cell
lines (MCF-7-RAdr); 24h after transfection, the reaction was
stopped by replacing the medium with normal growth medium
containing drug in concentration of 0.2mgml
–1. Cells were
trypsinised on the 72ndh and counted by CASY DT Cell Counter
(Innovatis AG, Reutlingen, Germany). We used negative siRNA-
treated (AllStars Negative Control siRNA, Qiagen GmbH) MCF-7-
RAdr cells, siRNA-untreated MCF-7-RAdr cells and siRNA-
untreated MCF-7 cells for controls with their doxorubicin-treated
analogue. For a statistical analysis, the number of living cells was
counted in each well. Experiments were carried out three times,
and each well was measured three times in each experiment. The
number of drug-treated cells was normalised to untreated cells in
siRNA-treated, negative siRNA-treated and siRNA-untreated wells.
The t-test was used for analysis of difference between groups.
Significance level was set at P¼0.05.
Validation on clinical samples
For in silico validation of the genes, a database containing
processed GEO microarray samples was established as described
earlier (Gyorffy and Schafer, 2009). Dataset includes GSE12276,
Affymetrix HGU133A microarrays
Feature-selection: PAM (top 100
transcripts)
Genes over-expressed in resistant vs
parental, but not in treated vs
untreated parental cell lines
Filtering of probe sets for
subunits of the proteasome
n=64
Quality control and RMA
normalisation
Overlap: PSMB7
gene
3 probe sets of proteasome subunits
are overexpressed
Survival analysis with
FDR<0.05, significant probe
sets n=12
GEO breast cancer samples
n=1592
Parental, resistant and 24 h-treated
parental cell lines
RNAi oligo
design
Kaplan–Meier
survival plot
Figure 1 Overview of the statistical analysis.
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sGSE16391, GSE12093, GSE11121, GSE9195, GSE7390, GSE6532,
GSE5327, GSE4922, GSE3494, GSE2990, GSE2034 and GSE1456.
First, genes were filtered to include only subunits of the
proteasome (n¼64). Then a survival analysis for each of these
probe sets were performed using BRB Arraytools 3.8.0-b_1
package (developed by Dr Richard Simon and Amy Peng Lam,
available at http://linus.nci.nih.gov/BRB-ArrayTools.html). The
false discovery rate (FDR) was set below 0.05. Finally, Kaplan–
Meier plots were drawn to illustrate the effect on survival in these
patients.
RESULTS
Identification of differentially regulated genes
To identify genes associated with the resistance to doxorubicin/
daunorubicin, we contrasted gene expression profiles of closely
related drug-resistant and -sensitive cell lines derived from breast,
pancreatic, colon and gastric cancer. For microarray analysis, RNA
was prepared from non-treated parental cells, from parental cells
treated with doxorubicin for 24h and from resistant derivatives
cultured continuously in the presence of doxorubicin at a
concentration that completely eliminated the sensitive cells. The
complete data set comprising raw data and Affymetrix .CEL files is
available in the GEO database (http://www.ncbi.nlm.nih.gov/geo/)
using the GEO accession number GSE3926. The prediction analysis
of microarrays was performed to pick the top 100 genes
differentially expressed in each sample set independent of tissue
origin. To visualise discriminatory expression changes, we
clustered the top genes (see Figure 2A and B). In these, three
probe sets representing proteasome subunits were expressed
stronger in doxorubicin-resistant cell lines, but not in doxorubi-
cin-treated parental cells (see arrows in Figure 2).
Autofluorescence of doxorubicin
Examining the effect of doxorubicin autofluorescence on MTT
results, there was no difference between doxorubicin-treated and -
untreated cells (P¼0.38). Fluorescence of doxorubicin supple-
mented L15 medium differed significantly from doxorubicin-
treated cells (Po0.01), but did not differ from untreated L15
medium (P¼0.065).
Prognostic potential of 64 proteasome subunits
The normalised gene expression of the GEO-downloaded 1592
samples was filtered to include only the proteasome subunits
present on the HG-U133A microarrays. The prognostic potential
for all 64 probe sets was computed by dividing the patients into
over- and underexpressed group as compared with the median
(thus, 531 patients were in each group). The analysis resulted in 12
significant genes below an FDR of 0.05. Of these, only one was also
detected by the microarray analysis (PSMB7), which was further
investigated. Immunocytochemistry confirmed the overexpression
of PSMB7 as observed on the microarrays (Figure 2C and D).
Survival of cells after gene silencing and treatment with
doxorubicin and paclitaxel
To examine the function of the PSMB7 gene in doxorubicin
resistance, we combined gene silencing with drug treatment to
assess its effect on cell survival. Viability of cells without
doxorubicin treatment was better in both siRNA-untreated and
siRNA-treated wells compared with cells with doxorubicin
treatment. A specific cytotoxic effect of negative control siRNA
was negligible as compared with the effect of gene-specific siRNA.
Data after normalization are presented in Figure 4; 79.8±13.3%
of resistance cells survived after doxorubicin treatment. Combined
with gene silencing, only 31.8±6.4% of the MCF-7-RAdr cells
survived. The significance between siRNA-treated and siRNA-
untreated MCF-7-RAdr cells after doxorubicin treatment was
P40.001. After doxorubicin treatment, 48.3±8.1% of sensitive
cells survived. A total of 73.3% of negative control siRNA-treated
cells survived. After combination of paclitaxel treatment and gene
silencing, 22.6±4% of the MCF-7-RAdr cells survived compared
with siRNA-untreated cells, whereas 43.8±6% of sensitive cells
survived (data not shown). Relative cell vitality of siRNA-treated
and siRNA-untreated MCF-7-RAdr cells after paclitaxel treatment
differed significantly (P¼0.03).
Biomarker potential of PSMB7 in clinical samples
To assess the prognostic power of PSMB7 gene in resistance,
clinical samples were used to validate the results of cell culture
model. We grouped the 1592 breast cancer patients on the basis of
the expression of PSMB7 using the Affymetrix HGU133A probe set
200786_at. Of these, 963 out of 1220 patients were ER positive and
187 out of 1156 lymph node positive. The average relapse-free
survival was 6.42 years. Unfortunately, detailed treatment history
was generally not available. Patients above the median had a
significantly shorter survival than patients below the median
(Po0.001) (Figure 5).
DISCUSSION
In our study we examined the function of the proteasome subunit
PSMB7 gene in drug resistance in breast cancer cell line and in
breast cancer patients. So far, no earlier study has risen up
concerning drug resistance neither for PSMB7 gene nor any of
proteasome subunits. In a cell culture model with a combination of
RNAi and drug treatment, we validated the causative function of
this gene in chemoresistance. The examination of 1592 breast
cancer patient showed that overexpression of this gene is
associated with poor prognostic outcome.
At the preliminary phase of this study, we contrasted the
expression profiles of four pairs of different human tumour cell
lines of gastric, pancreatic, colon and breast origin, their counter-
parts resistant to the topoisomerase inhibitors daunorubicin or
doxorubicin and the sensitive parental cells after a 24h-
chemotherapy treatment using Affymetrix HG-U133A microarrays.
We also performed additional analyses to exclude the influence of
doxorubicin autofluorescence (Karukstis et al, 1998) on our
results. Finally, we identified the top transcripts associated with
doxorubicin/daunorubicin resistance, but not with treatment
response. So far, the majority of microarray-based chemoresis-
tance-associated gene sets concentrated on finding genes asso-
ciated with resistance rather than on the difference between drug
response and drug resistance. Surprisingly, we have found genes
such as proteasome subunits coding PSMB7 and PSMD13 having
function in the mechanism of resistance that earlier have not been
described. Of these, only the expression of PSMB7 was able to
predict survival in clinical samples and was, therefore, further
investigated using RNAi.
The Homo sapiens gene PSMB7 encodes proteasome (also called
prosome or macropain) subunit b-type, 7. In the Haloarchaeon
Haloferax Volcanii proteasomal 20S, components are required for
cell growth (Zhou et al, 2008). Proteasome and tRNA modification
genes are co-transcribed, revealing that a number of additional
enzymes are co-regulated with proteasomes at the transcriptional
level in the same species (Gil et al, 2007). Other animal
experiments related to proteasome and immunology were made
on Japanese pufferfish (Clark et al, 2001) and zebrafish (Michalova
et al, 2000). The importance of monitoring proteasomes has
emerged in the last couple of years as it has an important function
in the degradation of many proteins involved in cell cycle
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Figure 2 Discriminating transcripts: (A) hierarchical clustering of all three groups (parental, treated parental, resistance cell line) against each other and (B)
hierarchical clustering of parental vs treated parental cell lines. Red arrows show appearance of three probe sets measuring proteasome subunits on
resistance-associated gene list. Immunohistochemical localization of PSMB7 expression in sensitive (C) and resistant cells (D). Reactions of cytoplasmic
localization were obtained for PSMB7 (green arrows).
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sregulation, apoptosis and angiogenesis. As these pathways are
fundamental for cell survival and proliferation, particularly in
cancer cells, the inhibition of proteasome might deliver an
attractive potential anticancer therapy. Proteolysis is conducted
by 20S proteasomes, complexes of 28 subunits arranged as a
cylinder in four heteroheptameric rings: a-1 to -7, b-1 to -7, b-1 to
-7 and a-1 to -7. The catalytic subunits are b-1 (PSMB6), b-2
(PSMB7) and b-5 (PSMB5). Three additional subunits, b-1i
(PSMB9), b-2i (PSMB10) and b-5i (PSMB8), are induced by
g-interferon (IFNG) and are preferentially incorporated into
proteasomes to make immunoproteasomes. PSMB11,o rb-5t, is a
catalytic subunit expressed exclusively in cortical thymic epithelial
cells (Murata et al, 2007).
The function of one of the catalytic subunits, the PSMB7 gene in
cancer is still an undiscovered spot of molecular biology. Its
overexpression is described in colorectal carcinomas, in both
cytoplasmic and nuclear region (Rho et al, 2008). After adaptation
of proteasome inhibitor expression of PSMB5 increased, but other
components of proteasome such as PSMB7 did not (Oerlemans
et al, 2008). Looking for tissue-specific alteration in proteasome
units, researchers treated mice with 3H-1,2-dithiole-3-thione
(D3T), which functions as a cancer preventive agent proved both
in animal and human studies; 24h later, expression of the 20S
catalytic core subunits PSMB5, PSMB6 and PSMB7 were increased
in liver, lung, small intestine and colon of mice (Kwak et al, 2007a).
Elevated expression of proteasome catalytic subunits led to
increase in proteasomal peptidase activities in these tissues. Oral
administration of D3T also exerted a pharmacodynamic action in
some brain regions of these mice and proteasomal peptidase
activities were significantly elevated in the cerebral cortex–
hippocampus. These results indicate that increased proteasome
expression by inducers may have a function in protection/
attenuation of protein aggregate-mediated disorders (Kwak et al,
2007b).
After in vitro inspection, we further validated the discriminating
function of differential PSMB7 expression in 1592 publicly
available microarrays . By dividing the patients as having over-
or underexpressed PSMB7 as compared with the median, we
achieved high significance. However, our approach is limited
Silencing Position of
siRNA (nt) Control
PSMB7
siRNA Control
PSMB7
siRNA
Sequence of siRNA (5′ to 3′)
200 AAGAGCAACTGAAGGGATGGT
548 AATGGCTGTATTTGAAGATAA
562 AAGATAAGTTTAGGCCAGACA
TSS
mRNA
Length:
1012 nt
204 PCR primers 404
200 562 548 Tested siRNA oligos
GAPDH
Figure 3 (A) Schematic view of PSMB7 gene with its eight exons. Splitting positions of tested siRNA oligos are shown (k); the most effective siRNA is
marked by continuously bordered box. Binding location of designed PCR primers specific for PSMB7 is shown under the gene by a broken line (k). Positions
of probe sequences of probeset 200786_at on Affymetrix HG-U133A array are also shown (m, match probes; W, junction probes, overlapping two
neighbouring exons). (B) Details of designed siRNA oligos. One out of three siRNA oligos (degrading at 548 nucleotide (nt)) showed effective silencing
compared with siRNA-untreated control. GAPDH was used as internal control for both untreated control and siRNA-treated samples. The effect of
silencing was 87% for siRNA binding at position 548.
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Figure 4 The effect of silencing of PSMB7 on doxorubicin resistance in
MCF-7 cells.
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grouped by the expression of PSMB7 (200786_at probe set) above or
below the median.
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sbecause of inadequate treatment information. A future study for
fine tuning of PSMB7 expression with RT–PCR in a large clinical
sample collection with detailed clinical follow-up could identify
exact cut offs for thresholds, which could validate and enhance its
discriminative potential in clinical use.
We might consider the idea to silence overexpressed PSMB7 as
part of a chemotherapy. However, despite promising in vitro
results, the establishment of effective RNAi conditions in vivo is
still complicated. A major impediment to the clinical use of RNAi
therapy is the need to deliver these macromolecules to each and
every cancer cell to trigger a direct and specific effect. Several
studies have shown in vivo efficacy in the delivery of siRNAs using
various strategies such as complexing siRNAs with cationic lipids,
nanoparticles, polyethyleneimine, cyclodextrin, chitosan and
collagen (Nguyen et al, 2008). Xenograft mouse model was also
effectively used in several studies (Xiao et al, 2008; Xie et al, 2008;
Zhang et al, 2008, 2009; Shi et al, 2009). In human beings, RNAi is
already in clinical use in therapy of macula degeneration and
respiratory syncytial virus infection, but so far no effective RNAi-
based inhibition of tumour progression is available.
As it was examined in the last decades, overexpression
of individual genes can be associated with resistance against
given agents. ABCB1 gene strongly correlates to chemoresistance
(Clarke et al 1992; Kamata et al, 2008; Larbcharoensub et al,
2008; Shi et al, 2008), TOP2A is a potential gene for predicting
anthracyclin resistance (Molina et al, 2005; Tanner et al, 2006;
Harris et al, 2007; Mano et al, 2007). Expression of metallo-
thioneins is linked to tamoxifen resistance (Surowiak et al, 2004),
and the gene Tau is a predictor of resistance against neoadjuvant
paclitaxel therapy (Rouzier et al, 2005; Andre et al, 2007). The
favourable outcome of this study suggests that PSMB7 gene
has an important function in predicting both doxorubicin and
paclitaxel resistance.
In summary, our findings support the function of the
proteasome in the development of chemotherapy resistance. High
PSMB7 expression is an unfavourable prognostic marker in breast
cancer.
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